Spero Therapeutics
SPRO
80 hedge funds and large institutions have $159M invested in Spero Therapeutics in 2020 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 34 increasing their positions, 12 reducing their positions, and 8 closing their positions.
250% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 8
183% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 12
71% more capital invested
Capital invested by funds: $93.2M → $159M (+$66.1M)
33% more funds holding
Funds holding: 60 → 80 (+20)
0.44% more ownership
Funds ownership: 56.73% → 57.17% (+0.44%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$1.4M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.28M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.2M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$927K |
| 5 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
+$869K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$3.83M |
| 2 |
AIC
AWM Investment Company
New York
|
-$1.71M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$863K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$643K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$560K |
SPRO Hedge Fund Activity: Q2 2020 in Review
80 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q2 2020, worth a combined $159M — up 71% from $93.2M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new SPRO positions and 8 closed out — a net gain of 20 holders — while 34 added to existing stakes and 12 trimmed.
The largest buyer was Aquilo Capital Management, adding an estimated $1.4M. The largest seller was VR Adviser, exiting entirely with an estimated $3.83M sold.
- 80 institutional investors held Spero Therapeutics (SPRO) as of Q2 2020, up from 60 in Q1 2020.
- Funds reported $159M of Spero Therapeutics stock for Q2 2020, up 71% quarter-over-quarter.
- 28 funds opened new Spero Therapeutics positions in Q2 2020 and 8 closed out, a net change of +20 holders.
- The largest Spero Therapeutics buyer in Q2 2020 was Aquilo Capital Management, an estimated $1.4M added.
- The largest Spero Therapeutics seller in Q2 2020 was VR Adviser, an estimated $3.83M sold.
Based on aggregated 13F filings for Q2 2020.